The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...

People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

FRIDAY, Dec. 27, 2024 (HealthDay News) -- People with multiple sclerosis (MS) have been concerned that a COVID-19 infection could cause the symptoms of their nerve disease to become even worse.

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.